Header

UZH-Logo

Maintenance Infos

The effect of zoledronic acid on serum biomarkers among patients with chronic low back pain and modic changes in lumbar magnetic resonance imaging


Koivisto, Katri; Karppinen, Jaro; Haapea, Marianne; Järvinen, Jyri; Kyllönen, Eero; Tervonen, Osmo; Niinimäki, Jaakko; Alini, Mauro; Lotz, Jeffrey; Dudli, Stefan; Samartzis, Dino; Risteli, Juha; Majuri, Marja-Leena; Alenius, Harri; Grad, Sibylle (2019). The effect of zoledronic acid on serum biomarkers among patients with chronic low back pain and modic changes in lumbar magnetic resonance imaging. Diagnostics, 9(4):E212.

Abstract

The aim of the current study was to compare changes in serum biomarkers, including inflammatory mediators, signaling molecules, growth factors and markers of bone turnover after a single intravenous infusion of 5 mg zoledronic acid (ZA, a long-acting bisphosphonate; n = 20) or placebo (n = 20) among patients with Modic changes (MC) and chronic low back pain in a randomized controlled design. The MCs were classified into M1, predominating M1, predominating M2, and M2. We measured the serum concentrations of 39 biomarkers at baseline, and one month and one year after treatment. After Benjamini-Hochberg (B-H) correction, we observed significant differences in three biomarkers over one year: Interferon-γ-inducible protein (IP10) had risen in the ZA group (p = 0.005), whereas alkaline phosphatase (AFOS) and intact procollagen I N-terminal propeptide (iPINP) had significantly decreased in the ZA group, but had not changed in the placebo group (p < 0.001 for both). Change in iPINP correlated with change in the volume of all MC and M1 lesions. ZA downregulated bone turnover markers as expected and, surprisingly, increased the chemokine IP-10 relative to placebo treatment. This adds to our knowledge of the effects of ZA on MC and the biomarkers that signal this process.

Abstract

The aim of the current study was to compare changes in serum biomarkers, including inflammatory mediators, signaling molecules, growth factors and markers of bone turnover after a single intravenous infusion of 5 mg zoledronic acid (ZA, a long-acting bisphosphonate; n = 20) or placebo (n = 20) among patients with Modic changes (MC) and chronic low back pain in a randomized controlled design. The MCs were classified into M1, predominating M1, predominating M2, and M2. We measured the serum concentrations of 39 biomarkers at baseline, and one month and one year after treatment. After Benjamini-Hochberg (B-H) correction, we observed significant differences in three biomarkers over one year: Interferon-γ-inducible protein (IP10) had risen in the ZA group (p = 0.005), whereas alkaline phosphatase (AFOS) and intact procollagen I N-terminal propeptide (iPINP) had significantly decreased in the ZA group, but had not changed in the placebo group (p < 0.001 for both). Change in iPINP correlated with change in the volume of all MC and M1 lesions. ZA downregulated bone turnover markers as expected and, surprisingly, increased the chemokine IP-10 relative to placebo treatment. This adds to our knowledge of the effects of ZA on MC and the biomarkers that signal this process.

Statistics

Citations

Altmetrics

Downloads

5 downloads since deposited on 06 Feb 2020
5 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:4 December 2019
Deposited On:06 Feb 2020 15:55
Last Modified:06 Feb 2020 15:55
Publisher:MDPI Publishing
ISSN:2075-4418
OA Status:Green
Publisher DOI:https://doi.org/10.3390/diagnostics9040212
PubMed ID:31817123

Download

Green Open Access

Download PDF  'The effect of zoledronic acid on serum biomarkers among patients with chronic low back pain and modic changes in lumbar magnetic resonance imaging'.
Preview
Content: Published Version
Language: English
Filetype: PDF
Size: 262kB
View at publisher
Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)